Frovatriptan succinate tablets and preparation method thereof

Abstract

The invention relates to frovatriptan succinate tablets and a preparation method thereof, and belongs to the field of a pharmaceutical preparation. The frovatriptan succinate tablets provided by the invention consist of active components, a diluent, an adhesive agent, a disintegrant and a lubricant, wherein the active components consist of frovatriptan succinate and cyproheptadine; the diluent consists of lactose and cane sugar; the adhesive agent comprises one or two of PVP-VA and Macrogol 6000; and the disintegrant comprises one or two of cross-linked PVP and sodium alginate. According to the frovatriptan succinate tablets disclosed by the invention, in a formula of the frovatriptan succinate tablets, the situations that the diluent consists of the lactose and the cane sugar, the adhesive agent comprises one or two of the PVP-VA and the Macrogol 6000, the disintegrant comprises one or two of the PVP and the sodium alginate, and the active components consist of the frovatriptan succinate and the cyproheptadine are determined for the first time. Through effect experiment research, the inventor finds that the effect for treating migraine by uniting the frovatriptan succinate and thecyproheptadine is notably increased, and the effect of synergetic effects is achieved.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a frovatriptan succinate tablet and a preparation method thereof. Background technique [0002] Migraine is a common chronic, recurrent disease that is widespread worldwide and seriously affects the quality of life of patients. [0003] Recently, it is believed that the pathogenesis of migraine originates from the central nervous system, and headache attacks are caused by cerebral cortex dysfunction accompanied by endocrine and vasomotor dysfunction. It has been confirmed that the 5-HT1 receptor is closely related to the onset of migraine. [0004] Frotriptan is a second-generation triptan drug, which is a selective 5-HT1B and 5-HT1D receptor subtype agonist, and has high affinity with 5-HT1B and 5-HT1D receptors, and has high affinity for 5-HT1B It is the strongest of the triptan drugs, and its mechanism of action is mainly to achieve the effect of treating migraine ...

AI Technical Summary

Problems solved by technology

However, it has not been clinically studied in combination with frovatriptan succinate for migraine

Images